Physician profile

James S Kohn

Surgery · Dallas, TX

NPI 1316901424

$16,140.02

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$2,000.00
Travel and Lodging$843.61
Food and Beverage$308.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Artegraft INC. $11,781.10 2019-2020
Lemaitre Vascular, INC. $2,843.61 2023 Artegraft Vascular Graft
Intuitive Surgical, INC. $762.44 2021-2023
Covidien Lp $336.49 2019
Abbott Laboratories $257.43 2019-2024 Diamondback Peripheral
Biotronik INC. $137.98 2022
Penumbra, INC. $20.97 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James S Kohn

$16,140.02

in general payments reported 2019-2025

Years
2019-2024
Top company
Artegraft INC.

https://glasscript.com/doctor/150474/james-s-kohn

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.